Elopag (Eltrombopag INN) 50 mg

£0.00

Elopag, also known as Eltrombopag, is prescribed for adults with chronic immune thrombocytopenia (ITP) who have not responded adequately to corticosteroids, immunoglobulins, or splenectomy. By acting as a thrombopoietin receptor agonist, Elopag enhances platelet production, crucial for managing ITP. The recommended dosage is 50 mg orally once daily, with adjustments based on individual response. Caution is advised regarding potential drug interactions and side effects, including thromboembolic events, hepatotoxicity, and cataracts. Close monitoring for adverse effects, particularly thromboembolic events and liver function, is essential. In case of overdose, supportive care is recommended due to the lack of a specific antidote.

Add to wishlist
Share
Category

    Indication: Elopag, also referred to as Eltrombopag based on the International Nonproprietary Name (INN), is prescribed for adults with chronic immune thrombocytopenia (ITP) who have not adequately responded to corticosteroids, immunoglobulins, or splenectomy.

    Pharmacology: Operating as a thrombopoietin receptor agonist, Elopag boosts platelet production by engaging with the thrombopoietin receptor’s transmembrane domain. This interaction initiates intracellular signaling cascades promoting megakaryocyte growth and differentiation, ultimately increasing platelet production.

    Dosage and Administration: Adults with chronic ITP typically receive Elopag orally at a recommended 50 mg dose once daily. Adjustments may be needed based on individual patient response to reach and maintain the desired platelet count. Elopag can be taken with or without food, ideally at the same time daily.

    Interactions: Elopag may interact with drugs affecting cytochrome P450 enzymes, notably CYP2C8 and CYP3A4. Caution is warranted when co-administering with potent CYP2C8 inhibitors or inducers, and careful monitoring is essential when combining with drugs increasing bleeding risk.

    Side Effects: Common side effects of Elopag include headache, fatigue, nausea, diarrhea, upper respiratory tract infections, and peripheral edema. Serious adverse reactions may comprise thromboembolic events, hepatotoxicity, and cataracts.

    Precautions and Warnings:

    • Thromboembolic events require close monitoring, particularly in patients with predisposing factors.
    • Regular liver function tests are recommended due to potential hepatotoxicity linked with Elopag use.
    • Ophthalmic monitoring is advised due to the risk of cataract development.
    • Caution is advised in patients with chronic liver disease, who may have an elevated risk of portal vein thrombosis with Elopag administration.

    Overdose Effect: In case of Elopag overdose, supportive care is advised. There is no specific antidote for Elopag overdose, emphasizing the importance of close monitoring for adverse reactions and prompt initiation of symptomatic treatment as necessary.

    Product Name

    Elopag

    Generic Name

    Eltrombopag INN

    Formulation

    Tablet

    Available Pack Size

    14 Tablets

    Available Strength

    50 mg

    Reviews

    There are no reviews yet.

    Be the first to review “Elopag (Eltrombopag INN) 50 mg”